has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens intramuscular route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role therapeutic cancer vaccine neoantigen synthetic long peptide vaccine A cancer vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells. This vaccine is a optimized neoantigen synthetic long peptide (SLP) vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. It can be used in combination with chemoradiation with temozolomide for patients with newly diagnosed glioblastoma. NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6332 cancer vaccine 6332 NCT: https://clinicaltrials.gov/study/NCT02510950 Jie Zheng NCT: https://clinicaltrials.gov/study/NCT05111353 Hayleigh Kahn